SARS-CoV-2 history, diagnosis, genetic diversity and treatment: a comprehensive review

 [1]Cai, M., Xie, Yan, Topol, E.J., & Al-Aly, Z. (2024). Three-year outcomes of post-acute sequelae of COVID-19. Nature Medicine, 30,1564-1573.

[2] Jebril, N.M, Al-Musawi, A.A., & Charles, B. Viral encephalitis associated with COVID-19 and following COVID-19 vaccination: a review of the literature and three cases. (2023). JUAPS, 17(2),1-4.

[3] Schalk, A. F., & Hawan, M.C. (1931).An apparently new respiratory disease of baby chicks. J.A. Veterinary Medicine Association,78,413-416.

[4] Bushnell, L.D., & B.C.A. (1933).Laryngotracheitis in chicks. (1933). Poul.Sci, 12(1),55-60.

[5] Almeida, J. D., & Tyrrell, D. A. J. (1967).The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture.J. Gen . Virol, 1(2),175-178.

[6]Berry, D.M., Cunningham, C.H., Hamre, D ., & Hofstad, M.S. (1968) .Virology : Coronaviruses .Nature, 210 (16)5168, 650.

[7]Wang, L., Wang, Y.,Ye, D., & Liu, Q.(2020). A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence.Int. J. Antimicrob. Agents,105948.

[8] Grant, W.B., Lahore, H., McDonnell, S.L, Baggerly, C.A., French, C.B, Aliano, J.L., &Bhattoa, H.P. (2020). Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients, 12(4), 1–19.

[9] Zhong, N.S., Zheng, B.J ., Li, Y. M., poon, L. L. M. Poon., Xie, Z.H., Chan, K.H ., Li P. H., Tan, S. Y., Chang, Q., Xie, J.P., Liu, X.Q., Xu, J ., Li, D.X Yuen, K.Y., Peiris, J . S . M ., & Guan, Y. (2003). Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February 2003. Lancet, 362(9393 1353–1358.

[10] Liu, D.X., Liang, J.Q., & Fung, T.S.(2021). HumanCoronavirus – E299, - O C43, - NL63, and – H KU1. ( Coronaviridae ). Encyclopedia of virology,428 – 440.

[11] Heurich, A., Hofmann-Winkler,H., Gierer,S., Liepold, T., Jahn, O ., & pohlmann , S .(2014). TMPRSS2 and ADAM17 cleave ACE2differentially and only proteolysis by TMPRSS2 augments entry driven by the severe Acute respiratory syndrome coronavirus spike Protein. J.Virol, 88(2),1293-1307.

[12]Simmons, G., Zmora, P., Gierer, S.,Heurich, A.,& Polmann, S.(2013). Proteolytic activation of the SARS-coronavirus spike protein: Cutting Enzymes at the cutting edge of antiviral research. Antiviral Res, 100(3), 605-614.

[13]Matsumoto, I .,Kamei, K ., Murase, T ., Yoshida, Yuta., Kawaguchi,K ., Matsumoto, M Satoi, S ., Takebe, A ., Nakai , T ., & Takeyama, Y.(2020) . Surgical treatment for chronic  pancreatitis: A single-center retrospective study in Japan. Journal of Hepato Biliary – Pancreatic  Sciences, 27(9), 632-639.

[14]Kawase, M., Shirato, K ., Hock , Lia .V.D.,  Taguchi,F ., & Matsuyama, S .(2012) . Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entryJournal of Virology,86(12), 6537- 6545.

[15Tebha, S. S., Tameezuddin, A., Bajpai, S., & ZZaidi, A.K. (2024). SARS-CoV-2- virus Structure and life cycle.Prog. Mol Biol Trans Sci, 202, 1-23.

[16]Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li,Y., Guan,W., Sang,L., Lu, J ., Xu, Y., Chen, G., Guo, H ., G, J ., Chen , Z., Zhao,Y., Li, S., Zhang, N., Zhong, N ., & He, J .(2020). Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Internal Medicine,180 (8), 1081–1089.

[17]Levenfus, I .,Ullmann, E.,Battegay, E., Schuurmans, M. M.(2020). Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score. Brazilian Journal of Infectious Diseases, 24(5),458-461.

[18] Abari-S,I., Khazaeli. S , Abari-S, F ., & Abari-S, A.(2020). Practical Guideline for Screening the Patients with SARS-CoV-2 Infection and Persian Gulf Criteria for Diagnosis of COVID-19. Advances in Infectious Diseases,10(3),67-93.

[19] World Health Organization (WHO). (2020a) Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019–nCoV in humans. http://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical.

[20] Nolan, T., Hands, R. E., & Bustin, S. A. (2006).Quantification of mRNA using real-time RT-PCR. Nat Protoc , 1, 1559-1582.

[21]Centers for Disease Control and Prevention (CDC) .(2020a).Real-Time RT – PCR panel for detection 2019-nCoV.

[22]To , K .K., Tsang, O.T., Yip, C.C., Chan, K.H.,

Wu, T .C., Chan, J.M., Leung, W.S., Choi,C.Y., Kandamby, D.H., Lung, D.C., Tam, A.R., Poon  R .W., Fung, A.Y., Hung, I.F., Cheng, V.C., Chan, J. F., &Yuen, K.Y. (2020).Consistent Detection of 2019 novel coronavirus in saliva. Clin Infect Dis, 71(15), 841-843.

[23]Jefferson, T., Spencer, E. A., Brassey, J., & Heneghan,C.(2021). Viral cultures for COVID-19 Infections Potential Assessment. A systematic review. Clin Infect Dis, 73(11), e3884-e3899.

[24]Jefferson, T., Spencer, E.A., Brassey, J., Onakpoya, I.J ., Rosa, E.C., Pluddemann,A., Evans, H.D., Conly, J. M., & Henegham, C.J Transmission of Severe Acute Respiratory Synodrome Coronavirus-2 ( SARS-CoV-2) From pre and asymptomatic infected Individuals: a systematic review.Clin Infect Dis ,28(2) 178-189.

[25] Watson, J., Whiting, P.F., Brush, J.E. (2020a). Interpreting a COVID-19 test result. BMJ, 12 369,m1808.

[26] Vogel, G.,(2020). New blood tests for antibodies Could show true scale of coronavirus pandemic. Science Magazine, Retrieved 6 April. http://www.sciencemag.org/news/2020/03/new-blood-tests-antibodies-could-show-true-scale-corona virus-pandemic.

[27]Kent,C.(2020).Different paths to the same Destination: Screening for Covid-19, http://www.medicaldevice-network.com/features/types-of-covid-19-test-antibody-per-antigen/.

[28] Word Health Organization(WHO).(2020b) . Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: Interim guidance.http://www.who.int/Publications/i/item/antigen-detection-in-the-Diagnosis-of-sars-cov-2infection-using-Rapid-immunoassays.

[29]Watson, J., Richter, A ., & Deek,J.T.(2020b). Testing for SARS-CoV-2 antibodies. BMJ,370,m3325. doi:http://doi.org/10.1136/bmj.M3325.

[30]Associated Regional and University Pathologists (ARUP) Laboratories.(2020). ARUP Laboratories Announces Nationwide Rollout of COVID-19 Antibody Testing, http://www.aruplab.com/news/4-16-2020/ antibody-testing-rollout.

[31]Cohen, J., (2020). Unprecedented nationwide   Blood studies seek to track U. S coronavirus Spread. Science (80-). http://doi.org/10.1126/  science.abc1319.

[32] Financial Times. (2020). Germany to run Europe's first large-scale antibody test Program.http://www.ft.com/content/fe211ec7- 0ed4-4d36-9d83-14b639efb3ad.

[33]Word health organization(WHO).(2020c).  Diagnostic testing for SARS-CoV-2 interim  guidance.http://www.who.int/publications/i/ item/diagnostic -testing-for-sars-cov-2).

[34]Beeching, N.J., Fletcher, T.E.,& Fowler, R.(2020). Coronavirus disease 2019.BMJ.Best Practice., http://bestpractice.bmj.com/topics/en-us/300168.

[35]Yuce, M., Filiztekin, E., & Ozkaya, K. G. (2021). COVID-19 diagnosis-A review of current methods, Biosensors, and Bio-electronics, 172(2021),112752.

[36]Soh, J.H., Chan, H.M., &Ying, J.Y.(2020).Strategies for developing sensitive and specific nanoparticle-based lateral flow assays as point-of-care diagnostic device. NanoToday, 30, 100831.

[37]Lin, D., Liu, L., Zhang, M., Hu, Y., Yang, Q., Guo, J., Dai, Y., Xu, Y., Cai, Y., Chen, X., Huang, K., & Zhang, Z., Chen, L.(2020). Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak. Eur J Clin Microbiol Infect Dis, 17,1-17.

[38]Huang, C.,Wang, Y., & Li, X., Ren, L., Zhao,J., Hu,Y., Zhang , L., Fan, G., Xu, J.,  Gu, X., Cheng, Z., Yu,T., Xia,J., Wei,Y., Wu,W., Xie,X., Yin, W., Li,H., Liu, M., Xiao,X.,&Cao,B.(2020).Clinical features of Patients infected with 2019 novel corona- virus in Wuhan.China. Lancet,395(10223), 497-506.

[39]Chen, N., Zhou, M., Dong, X., Qu, J ., Gong , F., Han, Y., Qiu, Y., Wang, J., Liu,Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical Characteristics of 99 case novel coronavirus Wuhan, China: a descriptive study.Lancet 395(10223),507-513.

[40]Song, F., Shi, N., Shan, F., Zhang ,Z., Shen, J., Lu , H., Ling, Y., Jiang, Y., & Shi,Y.  (2020)Emerging coronavirus 2019-nCoV Pneumonia . Radiology , 297(3),E(210 – 217 ) .

[41]Salehi, S., Abedi, A., Balakrishnan, S.,& Gholamrezanezhad, A.(2020). Coronavirus Disease(COVID-2019): A Systematic Review of Imaging Finding in 919 patients. American Journal of Roentgenology,215(1), 87-93.

[42]Ai, T., Yang,Z., Hou,H., Zhan, C., Chem , C., Lv, W.,Tao,Q., Sun, Z., & Xia,L.(2020). Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology, 296 (2), E32-E40.  Doi:10.1148/radiol.2020200642.

[43]Shelton, A., Parikh, S., Mims, C.,&  Quintero-Del-Rio, A. A. (2023)  challenging case of granulomatosis with  polyangiitis with cardiac involvement: a  rare case report. AME Case Rep, 7(8).doi: 10.21037/acr-22-29.

[44]Pormohammad, A., Ghorbani, S., Khatami, A., Razizadeh, M.H., Alborzi, E., Zarei,M., Idrovo,J.P., & Turner, R.J. (2021). Comparison of influenza type A and B with COVID-19: A Global Systematic Review And meta-analysis on clinical, laboratory And radiographic analysis finding. Rev Med Virol, 9(3), e2179.

[45]Babar, M., Jamil,H., Mehta, N., Moutwakil., A., & T.Q. (2024).short-and Long- Term Chest – CT Findings after  Recovery from COVID-19: A Systematic Review and Meta-Analysis. Diagnostics,14(6), 621.

[46]Lee, E.Y., Ng, M.Y., & Khong, P.L. (2020). COVID-19 pneumonia: what has CT taught us? The Lancet Infectious Diseases, 20(4),384- 385.

[47]Li, Y., & Xia, L. (2020a).Coronavirus Disease 2019 (COVID-19) Role of  Chest CT in Diagnosis and Management. American Journal Roentgenology, 214 (6), 1280- 1286.

[48]Oglat, A.A.(2024). Images of chest  Computer Tomography (CT) and  Radiation (X-ray) Demonstrating  Clinical Manifestations of COVID-19 Review Article, COVID, 4(7), 952-967.

[49]Savoia, P., Sawamura,M.V.Y., Monterio, R.A.de-Almeida., Duarte-N, A.N., Martin, M. de- Graca.M.,  Dolhnikoff,M., Mauad,T., Saldiva,P.H. N., Leite,C. da-Costa ., da-Silva, L.F.F., &Cardoso, E.F.(2024). Postmortem Chest computed tomography in  COVID-19: A minimally invasive  Autopsy method. Eur J Radio Open, 12 ( 100546).

[50] Al-Momani, H.(2024) A Literature on the Relative Diagnostic Accuracy Chest CT Scans versus RT-PCR Testing for COVID-19 Diagnosis Tomography,10(6):935-948.

[51] Udugama, B., Kadhiresan, P., Kozlowski, H.N., Malekjahani, A., Osborne, M., Li, V.Y., Chen, H., Mubareka, S., Gubbay, J.B., & Chan, W.C. (2020). Diagnosing COVID-19: The Disease and Tools for Detection. ACS Nano, 14 (4), 3822 – 3835.

[52] World Health Organization (WHO) 2020d. Use of chest imaging in COVID-19: a rapid Advice guide. http://www.who.int/Publications/ i/ item/ use-of-chest-imaging- in – covid-19.

[53]Moro, F., Buonseno,M ., Moruzzi, M.C., Inchingolo, R., Simargiassi,A., Demi, L., Larici,A.R., Scambia, G ., Lanzone,A., & Testa, A.C. (2020). How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol, 55(5) , 593- 598.

[54]Denina, M., Scolfaro, C., Silvestro, E., Pruccoli, G., Mignone, F., Zoppo, M., Ramenghi, U., & Garazzino, S.(2020). Lung Ultrasound in children with COVID -19. Pediatrics, 146 (1), e20201157.

[55]Mohamed,M .F.H., Al-Shokri, S., Yousaf, Z., Danjuma, M., Parambil, J., Mohamed, S., Mubasher, M., Dauleh, M.M., Hasanain, B., Alkahlout, M.A., & Abubeker, M.A.  (2020). Frequency of Abnormalities Detected by Point-of-Care Lung Ultrasound in Symptomatic COVID-19 Patients: Systematic Review and Meta-Analysis. AmJ Trop Med Hyg ,103(2),815-821.

[56]Ashraf, O., Virani, A., Cheema, T.(2021). COVID-19: An Update on the  Epidemiological, Clinical, Preventive, and  Therapeutic Management of 2019 Novel Coronavirus Disease.Crit Care Nurs  Q J,44(1),128-137.

[57]National Institutes of Health (NIH). (2020a). http://www.covid19treatmentguides.nih.gov/ therapeutic- management/.

[58]National Institute for Health and Care Excellence (NICE). (2020). http://www .nice.org.uk/guidance/ng163.

[59]Abuelgasim, H., Albury, C., & Lee, J. (2020). Effectiveness of honey for Symptomatic relief in upper respiratory Tract infections: a systematic review and Meta-analysis. BMJ Evid-Based Med,pp. bmjebm-2020-111336.

[60]Eccles, R., Boivin, G., Cowling, B.J, Pavia, A., & Selvarangan, R.(2023). Treatment of COVID-19 symptoms With over the counter (OTC).medicines Used for treatment of common cold and flu. Clinical Infection in Practice, 19 ( 100230).

[61]Mojoli, F., Mongodi, S., Orlando, A.,   Arisi, E., Pozzi, M., Civardi, L., Tavazzi, G., Baldanti, F.,Bruno,R., &  Iotti, G.A.(2020). COVID-19 Pavia Crisis Unit. Our recommendations For acute management of COVID-19. Crit Care, 24(1) , 207.

[62]National Institute of Health (NHI). (2020b). Oxygenation and  Ventilation. http:// www.covid19 Treatment guidelines. nil.gov/Critical – care /oxygenation and Ventilation/.

[63]Guerin, C., Reignier, J., Richard, J-Christophe, Beuret, P., Gacouin, A., Boulain, T., & Mercier, E. (2013). .prone positioning in severe acute Respiratory distress Respiratory distress syndrome. N Eng J Med, 368 (23), 2159-2168.

[64] Fan, E., Del, Sorbo, L., Goligher, E.C., Hodgson, C.L., Munshi, L., Walkey, A.J., Adhikari, N. K .J .,Amato, M.B.P., Branson, R., Brower, R. G., Ferguson, N.D.,Gajic, O., Gattinoni,L., Hess, D., Mancebo, J., Meade, M.O., Auley, D., Ranieri,V. M., Rubenfeld, G.D., Rubin, E., Seckel, M., Slutsky, A.S.,Talmor, D., Thompson, B.T., Wunsch, H., Uleryk, E., Brozek, J.,& Brochard, L.J.(2017) America Thoracic Society, European of Intensive care medicine, and Society of critical care medicine.An Official American Thoracic Society/European Society of Intensive care med-icine/Society of critical care medicine clinical Practice Guideline: Mechanical ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med, 195(9), 1253-1263.

[65]The Times.( 2020). Proning’ could keep corona- virus patients out of intensive care http://www. The times.co.uk/article/proning -could- keep Coronavirus-patients-out-of-Intensive-care-rn hsfm2rk.

[66]Sanders, J.M., Monogue, M.L.,Jodlowski, T.Z.,  & Cutrell, J.B.(2020).pharmacologic Treatments  For Coronavirus Disease 2019 (COVID-19): A  review. JAMA ,323 (18), 1824 – 1836 .

 [67]Siddiqi, H.K., & Mehra, M.R.(2020). Illness in native and Immunosuppressed states: clinical-therapeutic staging proposal. J Heart Lung Transplant,39 (5), 405- 407.

[68]Abdulsattar, J.O., Mutlk, S.T., & Abdulsattar,B.O. (2021). Coronavirus and New Potential Therap-eutic Targets: A Review.JUAPS, 15 (2), 1 -10 .

[69] Gilead Sciences.(2020). Remdesivir(VEKLURY)  http://www.acccessdata.Fda.gov/drugsatfda.docs /label/2020/214787OrigIs000IbI.pdf.

[70]Wang, M., Cao, R., Zhang, L ., Yang, X., Liu, J ., Xu, M., Shi, Z., Hu, Z., Zhong, W.,  & Xiao, G.(2020a).Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res,30 (3), 269- 271.

[71]Williamson, B, N ., Feldmann, F., Schwarz, B., White-M, K., Porter, D.P.,Schulz,J., Doremalen, N.V., Leighton, L., Yinda, C.K  ., Perez-P,L ., Okumura,A., Lovaglio,J., Hanley, P.W., Saturday, G., Bosio, C.M.,Anzick,S., Barbian, K., Cihlar, T., Martens, C., Scott, D.P., Munster, V.J., & wit, E. D.(2020). Clinical benefit of remdesivir in Rhesus macaques infected with SARS-Co V-2). Nature, 585 (7824) , 273- 276.

[72]American Society of Health- System Pharmacists (ASHP). (2021a). Lopinavir and Ritonavir. http://medlineplus.gov/ druginfor /Meds/a602015.html.

[73]Chen, F., Chan, K.H., Jiang, Y.,Kao, R. Y., Lu, H.T., Fan, K.W.,Cheng, V.C., Tsui, W.H.,Hung, I.F ., Lee, T.S., peiris, J. S.,& Yuen , K.Y.(2004), In vitro susceptibility of 10 clinical Isolates SARS coronavirus to selected anti- Viral compounds. J Clin Virol, 31(1) , 69-75.

[74]Liu, J ., & Wang , X.J., (2020). Potential Inhibitors against 2019-nCoV coronavirus M protease from clinically approved med-iciness. J Genet Genomics, 47(2) , 119-121.

[75]Istampoulouoglou, I., Zimmermanns, B., Grandinetti, T., Marzolini, C., Harings-Kaim, A., Koechlin-Lemke, S., Scholz, I., Bassetti,S.,  & Leuppi-Taegtmeyer, A.B. (2021).Cardio-Vascular adverse effects of lopinavir/Ritonavir and hydroxychloroquine in COVID -19 patients: Cases from a single pharmaco-vigilance centre . Glob Cardiol Sci Pract, 2021(2) , e 202111.

[76]National Institutes of Health (NIH). (2020n). Lopinavir/Ritonavir and other HIV Protease Inhibitors.http://www.covid19treatmentguide Lines.nih.gov/antiviral – therapy/lopinavir-Ritonavir-and-other-hiv-protease -inhibitors.

[77]Vincent, M.J., Bergeron, E., Benjannet, S., Erickson, B.R., Rollin, P.E., Ksiazek, T.G., Seidah, N.G., & Nichol, S.T. (2005).Chloro-Quine is a potent inhibitor of SARS corona- virus infection and spread. Virol J, 2,69.

[78]Chen, Y., Li, M.X., Lu, G.D., Shen, H.M., & Zhou, J.(2021). Hydroxychloroquine/Chl- oroquine as Therapeutics for COVID-19: Truth under the Mystery. Int J Biol Sci  17(6) , 1538 – 1546 .

[79]Liu,J., Cao, R., Xu,M., Zhang,H., Hu,H., Li, Y., Hu,Z., Zhong, W., & Wang, M.(2020).  Hydroxychloroquine, a less toxic derivative of Chloroquine is effective in inhibiting SARS-CoV-2 infection in vitro. cell discovery, 6,16.

[80]Omura, S., & Crump , A.(2014). Ivermectin: Panacea for recourse -poor communities? Trends Parasitol , 30 (9) , 445 – 455.

[81]Fritz, M.L., Siegert, P.Y., Walker , E.D., Bayon, M.N., Vulule, J.R., & Miller, J.R.(2009).Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 103 (6), 539 – 547.

[82]Yang, S.N.Y., Atkinson, S.C., Wang, C., Lee,  A., Bogoyevitch, M.A., Borg, N.A., & Jans,  D.A.(2020). The broad-spectrum antiviral ivermectin targets the host nuclear transport importin alpha/ beta1 heterodimer, Antiviral Res, 177, 104760.

[83]Clay, L., Druce, J.D., Catton, M.G., Jans, D.A., & Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, 178, 104787.

[84]Zhong, J., Tang. J ., Ye, C., & Dong .L. (2020). The immunology of COVID-19: Immune Modulation an option for treatment? Lancet Rheumatology, 2 (7), e436–e438.

[85]Wang, X., Guo, X., Xin, Q., Pan,Y., Hu, Y.,Li, J.,Chu, Y., Feng, Y., & Wang, Q. (2020b). Neutralizing Antibody Responses to severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and conval -escent patients. Clin Infect Dis, 71(10),2688 – 2694.

[86]Mair-Jenkins, J., Saavedra-Campos, M., Baillie. J.K., Cleary, P., Khaw, F.M.,Lim,W.S., Makki, S., Rooney, K.D., Nguyen-Van-Tam, J.S., &Beck, C. R., Convalescent Plasma Study Group. The effectiveness of convalescent plasma and  hyperimmune immunoglobulin for the treat-  ment of severe acute respiratory infections of  viral etiology : systematic review and explorat-ory meta- analysis . J Infect Dis ,211(1),80-90 .

[87]Shetty,A.K.(2020). Mesenchymal Stem Cell Infusion Shows Promise for Combating Coron-avirus (COVID-19)- Induced Pneumonia . Aging Dis, 11 (2), 462 – 464.

 [88]Peng, H.T., Rhind, S.G., & Beckett, A.(2021). Convalescent. Plasma for the Prevention and  Treatment of COVID-19: A Systematic Review and Quantitative Analysis. JMIR Public Health Surveill,7(4), e25500.

[89]Lukomska,B.,Stanaszek , L., Zuba- Surma, E., Legosz, P., Sarzynska, S.,& Drela, K .(2019). Challenges and Coronaviruses in Human Mesenchymal Stem Cell Therapy.Stem Cells Int, 9, 9628536.

 [90]Wei, J., Shang, R., Wang, J ., Zhu, S., Yin, J.Q., Chen, Y., Zhao, Y ., & Chen. G. (2022).ACE2 overexpressing mesenchymal stem Cells alleviates COVID-2019 lung injury by inhibiting pyroptosis. I science25 (4), 104046.

[91]Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J ., Qin, Y., Zhang, X., Yan, X., Zeng, X., & Zhang, S. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019(COVID-19): The perspectives of clinical immunologists from China, Clin  Immunol, 214, 108393.

 [92] Channaappanavar, R., & Perlman, S.(2017). Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 39,529 – 539.

[93]Horby, P., Faust, S.N., Lim, W.S., Emberson,J., Mafham,M., Bell,J.L., Linsell,L., Staplin,N.,  Brightting,C.E.,Ustianowski,A.,Elmahi,E., Prudon, B., Green,C.A.,Felton,T.W., Chadwick,  D.,Rege, K., Fegan,C., Chappell,L.C., Jaki,T., Jeffery,K., Montgomery,A., Rowan,K.M., Juszczak,E., Baillie,K., Haynes, R., Landay,M.J., Henshall,D., Vatish, M., & Ortega, P.R.(2020). Dexamethasone in hospitalized patients with COVID-19. The New – England Medical Review  and Journal, 384 (4).

 [94]Shakoory,B., Carcillo, J.A., Chatham, W.W.,Zhao, H., Dinarello, C. A., Cron, R.Q., &Opal, S.M.(2016). Interleukin-1 Receptor Blockade is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a prior phase III Trial. Crit Care Med.44 (2)275-281.

 [95] Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., Zhang, X., Pan, A.,& Wei, H. (2020). Effective treatment of Severe COVID-19 Patients with tocilizumab. Proc Natl Acad Sci U S A, 117 (20), 10970 – 10975.

[96]Zhou, Q., Chen, V., Shannon, C.P., Wei, X-S., Xiang, X., Wang, Z-H., Tebbutt,S. J., Kollmann, T.R.,& Fish, E. N.(2020). Interferon-α2b Treatment for COVID-19. Front. Immunol, 11, 1061.

[97]Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., & Zhou, J.(2020). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, Randomized controlled trial. J Allergy Clin Immunol, 146 (1), 137 – 146.

[98]National Institutes of Health (NIH). 2020f http://www.covid19treatementguidelines.nih.gov/immune-based therapy/immunomodulator/corticosteroids/.

[99]Noreen, S., Maqbool, I.,& Madni, A.(2021). Dexamethasone: Therapeutic potential risks And future projection during COVID-19 Pandemic. Eur J Pharma, 894, 173854.

[100]National Institutes of Health (NIH). 2020fg http://www.covid19treatementguidelines.nih.gov/immune-based therapy/immunomodulator/interferons/.

[101] Food and Drug Administration (FDA).(2012).  Anakinra (Kineret).http://www.accessdata. Fda.gov/drugsatfda_docs/label/2012/1039 50s51361b1.pdf.

 [102]Canna, S.W., Behrens, E.M.(2012).Making  Sense of the cytokine storm: a conceptual Framework for understanding, diagnosing, and treating hemophagocytic syndromes  Pediatric Clinics of North America,59 (2),329 – 344.

[103]Eloseily, E.M., Weiser, P., Crayne, C.B., Haines, H., Mannion, M.L., Stoll, M.L.,Beukelman, T., Atkinson, T.P.,&Cron,R. Q.(2019). Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.Arthritis Rheumatol,72 (2), 326 – 334.

[104]Koçak, Tufan. Z., Kayaaslan, B.,& Mer, M., (2021). COVID-19 and Sepsis.Turk J Med Sci, 51 (SI-1), 3301 – 3311.

[105] Monteagudo, L.A., Boothby, A.,&Gertner, E.(2020). Continuous Intravenous Anakinra Infusion to Calm the Cytokine Strom in  Macrophage Activation Syndrome. ACR  Open Rheumatol, 2 (5) ,276 – 282.

[106]Yoshikawa, T., Hill, T., Li, K., Peters, C.J., &Tseng, C.T.(2009). Severe acute respiratory syndrome (SARS) coronavirus-induced lung  epithelial cytokines exacerbate SARS  pathogenesis by modulating intrinsic  Functions of monocyte-derived macrophages And dendritic cells. J Virol, , 83 (7) , 3039 –3048.

 [107]Huang, C., Wang, Y., Li, X., Ren, L., Zhao, Hu, Y., Zhang, L ., Fan, G, et al . (2020). Clinical Features of Patients infected with 2019 novel coronavirus in Wuhan , China  . Lancet, 395 (10223), 497 – 506.

[108]Russell, B., Moss, C., George, G., Santaolalla , A., Cope, A., Papa, S.,& Hemelrijck, M. V. (2020). Associations between immune- suppressive and stimulating drugs and novel COVID-19 a systematic, review of current  Evidence. Ecancer, 14, 1022.

[109] Wang, Y., Zhang, L. L., Champlin, R. E.,&Wang, M. L.(2015). Targeting Bruton's  tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther,97(5) , 455 – 468.

[110] Bousoik, E., Montazeri , A.H. (2018). Do Do we know jack "about JAK? A closer at JAK/STATsignaling pathway.Front Oncol 8, 287.

 [111]Han, H., Yang, L., Liu, R., Liu, F.,Wu, K.L., Li, J., Liu, X.H., & Zhu, C.L.(2020). Prominent changes in blood coagulation Of patients with SARS-CoV-2 infection  ClinChem Lab Med,58 (7) 1116 - 1120.

[112] Tian, S., Hu, W., Niu, L., Liu H.,& Xu, H., (2020).Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in two Patients With lung Cancer . J Thorac Oncol,15 (5), 700 – 704.

[113]Ware, L. B.(2006).Pathophysiology of acute Lung injury and the acute respiratory distress Syndrome. Semin Respir Crit Care Med, 27(4)337 349.

[114] Thachil, J., Tang, N., Gando, S., Falanga A, Cattaneo, M., Levi, M ., Clark, C., &Iba, T., (2020).ISTH interim guidance on recognition a and management of coagulopathy in COVID-19. J Thromb Haemost,18(5), 1023 – 1026.

[115]Galali, Y., Davies, S.J., Balaky. H.H.,&Jabbar, A.A. (2024). Anti-Viral Immune Enhancer Properties of some Micro- Nutrients and Functional Herbs With the Potential to Augment the Treatment of COVID-19 Patient .JUAPS . 18 (1), 86 – 105.

[116]Boretti, A.,& Banik,B.K . (2020). Intravenous Vitamin C for reduction of cytokines storm in Acute respiratory distress syndrome. Pharma. Nutrition, 21, 100190.

[117]Wei,X.B., Wang, Z.H., Liao, X.L .,Guo,W.X., Qin, T.H., & Wang, S.H.(2020). Efficacy of Efficacy of vitamin C in patients with sepsis: An updated meta-analysis.Eur J Pharmacol 5 (868), 172889.

[118]Fisher, B.J., Seropian, I.M., Kraskauskas, D., Thakkar, J.N., Voelkel, N.F., Fowler, A.A.,&3rd, Natarajan.(2011). Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med,39 (6),1454 – 1460.

[119] Aranow, C. (2011).Vitamin D and the immune System. J. Investig Med, 59 (6), 881 – 886.

[120]National Institutes of Health. (NIH). (2020I) Interleukin-6 Inhibitors http://www.covid19treatmentguide.nih.gov/immune-based-therapy/immunomodulators/interleukin-6- inhibitors/.

[121]Fisher, S.A., Rahimzadeh, M., Brierley, C., Gration, B., Doree, C., Kimber, C.E., Plaza, Cajide.A., Lamikanra, A.A., & Roberts,D.J. (2019). The role of vitamin D in increasing Circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review PLoS One, 14 (9), e0222313.

[122]Martineau, M.J., Aryal,K., Alhazzani, W., AlexanderP.E. Aloia,J.F., Raz,G.D., Esposito , S . et, al.(2017). Vitamin D supplementation Prevent acute respiratory tract infections : Systematic review and meta-analysis of Individual participant data. BMJ, 356(1),6583.

[123]Ross, A.C., Taylor, C.L., Yaktine AL, De. Valle, H.B.eds (2011).Calcium Vitamin C file:///C:/Users/spiderhouse/Downloads/ Bookshelf_NBK56070.pdf.

[124]Wessel, I., Maywald,M.,& Rink, L.(2017). Zinc as a gatekeeper of immune function. Nutrients. 9, 1286.

[125]Maywald, M., Wessels, I., & Rink,L.(2017). Zinc signals and immunity. Int J Mol Sci,18, 2222.

[126]Bailey, R.L., West, K.P. Jr.,& Black, R.E. (2015).The epidemiology of global Micronutrient deficiencies. Ann Nutr Metab, 66 (Suppl2), 22-33.

[127] Yasuda, H., & Tsutsui, T.(2016). Infants and elderlies are susceptible to zinc  deficiency.

[128]Gammoh, N.Z., &Rink,L. (2017). Zinc in Infection and inflammation.Nutrients, 9,624.

 [129]Te Velthuis, A.J.,Van Den Worm , S.H., Sim, A.C., Baric, R.S., Snijder, E.J., &Van Hemert , M.J. (2010). PLoSPathog , 6 , e1001176.

 [130]Saghir,S.A., Al Gabri,N.A ., Alagaway, M.M., Attia, Y.A., Alyileili, S.R., Elner, S.S. et, al (2021).Chloroquine and Hydroxychloroquine for the prevention and Treatment COVID-19: A Fiction, Hope or Hype? An Updated Review. Therapeutics and Clinical Rick Management, 17, 371 – 387.

 [131]Xue, J., Moyer, A., Peng, B., Wu, J., Hannafon, B.N.,& Ding, W.Q.(2014). Chloroquine is a zinc ionophore. PLoS One, 9, e109180.

 [132]Guastalegname, M.,& Vallone, A.(2020). Could chloroquine/hydroxy be harmful in Coronavirus disease 2019(COVID-19) treatment? Clin Infect Dis, 71(15)888- 889.

[133]William, T. H., Alessandro. M., Carabelli , Ben. J., Ravindra, K ., Gupta, C., Thomson, E.M., Ewan, M. H., Catherine, L., Richard, R., &Andrew. R . (2021). COVID-19 Genomics UK (COG-UK) Consortium, S.J.P., & David, L.R. SARS-CoV-2 variants, spike mutations, and immune escape. Nature Review Micro, 19, 409 – 424.

[134] Jingsong , Z., Yang , Z., Jun-Yan, K.,  Shuiye,C., Yongqun,H., Benhao,H.,  Mo-Fang, L., Lina, L., Li, Li., Z,Yi., & Luonan, C. (2021).Potential transmission Chains of variant B.1.1.7 and co-mutation Of SARS-CoV-2.. Cell Dis, 7(44) , 1-10.

 [135]Daming,Z., Wanwisa,D., Piyada,S.,  Jingshan, R., David, I.S ., Gavin, R.S., Mentzer,A.J., Ginn, H. M., Zhao , Y., Duyvesteyn, H.M.E , et , al . (2021). Evidence of escape of SARS-CoV-2 Variant B.1.351 from natural and  Vaccine-induced sera.Cell, 184 (9), 2348 – 2361

[136]da Silva, J.C., Félix, V.B., Leão, S.A.B.F., Trindade-Filho ,E.M.,& Scorza ,F.A.(2021). New Brazilian variant of the SARS-CoV-2(P1/Gamma) of COVID-19 in Alagoas State . Braz J Infect Dis, 25(3) , 101588. .

[137]Petra,M.,Steven, A.K.,& Ravindra, K.G., Dhar,M.S.,Papa,G.,Meng,B.,Ferreia, I.A. T.M., Datir, R., Collier, D.A, et . al (2021).  SARS-CoV-2 B.1.617. 2 Delta variant Replication and immune evasion. Nature,  599(7883), 114 – 119.

[138] Amy Barrett.,(2021). From Alpha to Omicron, everything you need to know about the new coronavirus variant., http://www.gavi.org/ vaccines work/alpha- omicron- everything – you- need-know- about – coronavirus-  variant.

[139] Rana,R., Kant,R., Huirem, R.S., Bohra,D.,& Ganguly, N.K.(2022). Omicron variant:  Current insights and future directions MicroRes, 265, 127204.

[140]Musafer, H.K., Abdulrazaq, R.A., Ali, B.M.,& Abdulridha, G.K.(2021) . Review of Covid-19 vaccines . JUAPS , 15(2) , 35-44.

[141] Pfizer – BioTech., (2021). COVID-19 Vaccine ( link is external ) (U.S. Food and Drug Administration).

[142] Xia, S., Zhang, Y., Wang, Y., et. al.(2020).  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a  Randomized, double-blind, placebo- Controlled, phase 1/2 trial. Lancet Infect Dis 15, S1473- 3099 (20), 30831- 30839.

[143]Wang, H., Zhang, Y., Huang, B., et. al (2020). Development of an inactivated vaccine Candidate, BBIBP- Cor, with potent Protection against SARA-CoV-2. Cell,6,182(3), 713 – 721e.

[144]Coughlan, L., Sridhar, S Payne, R., et al. (2018). Heterologus two-dose vaccination With simian adenovirus and poxvirus vectors Elicits long-lasting cellular immunity to Influenza virus.A in healthy adults. E Bio.Medicine 29, 146-154.

[145] Doremalen, N., Haddock, E., Feldmann,F., et  Al.(2020). A single dose of chAdoX1 MERS  Provides protective immunity in rhesus  Macaques,. Sci Adv, 6, eaba8399.

[146]Anderson, E.J., Rouphael, N. G ., widge , A.T., et . al (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA -1273vaccine in older adults. N Engl J Med, 383(25) , 2427 – 2438.

[147]Moderna Therapeutics. Moderna Announces longer shelf life for its COVID-19 vaccine candidate at Refrigerated temperature [Internet]. Moderna. (2020). [ cited 2020 Dec], Available from http://investors. Modernatx.com/news-releases/news- Releases – details/ moderna- announces  -longer- shelf- life – its- covid-19- Vaccine.